Credit: Boehringer Ingeheim. The high-concentration formultion (100mg/mL) is available as a prefilled syringe (40mg/0.4mL) or prefilled autoinjector. Cyltezo is an interchangeable biosimilar and can ...

Credit: Fresenius Kabi. Tyenne is now available as a 20mg/mL single-dose vial (80mg/4mL, 200mg/10mL, or 400mg/20mL) for further dilution prior to IV infusion. The biosimilar received FDA approval on ...

Boehringer Ingelheim has received the Food and Drug Administration’s blessing for the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable ...

Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...

The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of adalimumab-adbm (Cyltezo), a biosimilar of Humira, Boehringer Ingelheim announced. This ...

On April 15, 2024, Fresenius Kabi announced the U.S. launch of its ACTEMRA biosimilar, TYENNE (tocilizumab-aazg) as an intravenous formulation. As we previously reported, Fresenius Kabi received FDA ...

Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV ...

Alteogen said on the 2nd that it filed an international patent (PCT) for a formulation technology that can develop a high-concentration biosimilar (copycat drug) of the eye disease treatment "Eylea." ...

RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of ...

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...